| Similar Articles |
|---|
 |
The Motley Fool
July 22, 2011 |
Green Mountain Coffee Roasters Earnings Preview Investors are on the edge of their seats, hoping that Green Mountain Coffee Roasters will top analyst expectations for the fourth consecutive quarter. on Wednesday, July 27.   |
The Motley Fool
March 31, 2008
Brian Lawler |
A Little Funding for Pharmasset Development-stage drugmaker Pharmasset may be on to something with its hepatitis C compounds. |
The Motley Fool
July 21, 2011 |
Cabot Earnings Preview Cabot, a global specialty chemicals and performance materials company, will unveil its latest earnings on Tuesday. |
The Motley Fool
October 27, 2009 |
3 Stocks Hitting High Notes These stocks are reaching for the stars and hitting 52-week highs: lululemon athletica inc... Celanese Corp... Cabot Oil & Gas... |
The Motley Fool
January 17, 2008
Brian Lawler |
The Good Times Roll for Pharmasset Shares ride high after the company releases positive clinical trial data. |
The Motley Fool
July 19, 2011 |
Microsoft Earnings Preview Microsoft will unveil its latest earnings on Thursday, July 21. |
The Motley Fool
July 11, 2011 |
Washington Federal Earnings Preview Washington Federal didn't hit the Street's expectations last quarter, but investors hope that it will rebound this quarter. The company will unveil its latest earnings on Thursday. |
The Motley Fool
October 28, 2009
Toby Shute |
Still No Love for This Gas Company Cabot's going to catch the Street's eye eventually. Be there first. |
The Motley Fool
September 30, 2009
Toby Shute |
Marcellus Shaping Up as a Frac Battleground Tensions rise as state oil and gas regulators crack the whip. |
The Motley Fool
December 28, 2011
Amanda Buchanan |
Was 2011 a Good Year for Coffee Holding? Let's reflect on the company's roller-coaster performance over the past year. |
The Motley Fool
October 24, 2007
Brian Lawler |
Pharmasset on the Fast Track Hepatitis and HIV drug developer announced that its lead antihepatitis C compound has received fast-track status from the FDA. The decision is not fantastic news, but it could help. Investors, take note. |
The Motley Fool
July 30, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Dougherty's Green Mountain Coffee recommendation tastes stale. |
The Motley Fool
November 23, 2009 |
Casual Male Retail Group, Inc.: Warming Up or Cooling Off? What we think about the direction of this company's stock. |
The Motley Fool
November 23, 2009 |
Commercial Vehicle Group, Inc.: Warming Up or Cooling Off? Take the temperature of your stock. |
The Motley Fool
July 13, 2011
David Williamson |
Roundtable: The Biggest Risks in Biotech Three biotech companies to steer clear of. |
The Motley Fool
November 30, 2011
David Williamson |
5 Top November Health-Care Stocks These stocks had an amazing month. |
The Motley Fool
January 9, 2012
David Williamson |
Inhibitex Is an Instant Double Some takeout rumors do come true. |
The Motley Fool
December 9, 2011
Dan Caplinger |
Protect Your Stocks in a Scary Market Buying put options is expensive, but it can still be a good move. |
The Motley Fool
May 2, 2011
Isac Simon |
Cabot Oil & Gas Is Not Delivering the Goods The company needs to look into its operations to gain efficiency and convert revenues into more profits. |
The Motley Fool
November 21, 2011
David Williamson |
Pharmasset Acquired, Shares Jump 85% Gilead Sciences buys Pharmasset and hepatitis C drug PSI-7977. |
The Motley Fool
September 11, 2007
Brian Lawler |
Score One for Pharmasset Shares of Pharmasset were up after the company announced impressive results for its Hepatitis C virus drug candidate R7128. Investors should continue to watch closely. |
The Motley Fool
June 3, 2009
Rick Aristotle Munarriz |
Barron's Doesn't Know Beans About Good Coffee Green Mountain isn't as overvalued as the financial publication Barron's thinks. |
The Motley Fool
August 26, 2010
Jeremy Phillips |
Time to Short Green Mountain Coffee Roasters? Does this highly shorted stock deserve it? |
The Motley Fool
July 27, 2011
Alexander Crawford |
Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve? |
The Motley Fool
November 5, 2011
David Williamson |
Inhibitex Investors: Why Shares Popped 115% Great results for INX-189 send shares skyward. |
The Motley Fool
October 31, 2011
Brian Orelli |
Gunning for the Leaders Hepatitis C drugs take center stage. |
The Motley Fool
November 21, 2011
David Williamson |
Market Volatility = Biotech Opportunity Gilead buys Pharmasset, Spectrum gets a break, and Eylea's approved. |
The Motley Fool
July 23, 2010
Toby Shute |
Cabot's Promising, but Problematic I want to like Cabot Oil & Gas, but the regulatory violations make me shake my head. |
The Motley Fool
August 4, 2006
Alyce Lomax |
Climbing Green Mountain Is this socially responsible coffee company too high an altitude for investors? |
The Motley Fool
November 15, 2011
Vibhuti Shah |
An Opportunity Is Brewing for This Stock With shares of the specialty coffee company Green Mountain falling recently, has the company turned bitter for investors? |
The Motley Fool
July 29, 2011
Chris Baines |
Green Mountain: Too Hot to Touch Despite soaring shares, I wouldn't buy the coffee contender. |
The Motley Fool
March 4, 2011
Sean Williams |
Of These 4 Coffee Stocks, Only This 1 Is a Buy Which one of these stocks will grind out profits for your portfolio? |
The Motley Fool
May 1, 2009
Toby Shute |
Pounce on These Marcellus Players Range Resources and Cabot Oil & Gas may call Texas home, but don't let the zip codes fool you. These independent oil and gas shops have deep roots in Appalachia and are feeling right at home in the race to unlock the mighty Marcellus shale. |
The Motley Fool
May 10, 2006
Alyce Lomax |
Slow Roast at Green Mountain Did Green Mountain serve up a lukewarm quarter? There's ample time for interested investors to watch and wait. |
